Skip Navigation


Human Molecular Genetics Advance Access originally published online on July 22, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
12/18/2379    most recent
ddg240v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Patek, C. E.
Right arrow Articles by Hooper, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patek, C. E.
Right arrow Articles by Hooper, M. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2003, Vol. 12, No. 18 2379-2394
DOI: 10.1093/hmg/ddg240
© 2003 Oxford University Press

Murine Denys–Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis

Charles E. Patek1, Stewart Fleming2, Colin G. Miles3,{dagger}, Christopher O. Bellamy4, Michael Ladomery3,{ddagger}, Lee Spraggon3, John Mullins5, Nicholas D. Hastie3 and Martin L. Hooper1,*

1Sir Alastair Currie Cancer Research UK Laboratories, Molecular Medicine Centre, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK, 2Department of Pathology, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, UK, 3MRC Human Genetics Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK, 4Division of Pathology, The University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG, UK and 5Molecular Physiology Laboratory, Wilkie Building, University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG, UK

Received May 28, 2003; Revised June 19, 2003; Accepted July 10, 2003

Denys–Drash syndrome (DDS) is caused by dominant mutations of the Wilms' tumour suppressor gene, WT1, and characterized by a nephropathy involving diffuse mesangial sclerosis, male pseudohermaphroditism and/or Wilms' tumourigenesis. Previously, we reported that heterozygosity for the Wt1tmT396 mutation induces DDS in heterozygous and chimeric (Wt1tmT396/+{leftrightarrow}+/+) mice. In the present study, the fate of Wt1 mutant cells in chimeric kidneys was assessed by in situ marker analysis, and immunocytochemistry was used to re-examine the claim that glomerulosclerosis (GS) is caused by loss of WT1 and persistent Pax-2 expression by podocytes. Wt1 mutant cells colonized glomeruli efficiently, including podocytes, but some sclerotic glomeruli contained no detectable Wt1 mutant cells. The development of GS was preceded by widespread loss of ZO-1 signal in podocytes (even in kidneys where <5% of glomeruli contained Wt1 mutant podocytes), increased intra-renal renin expression, and de novo podocyte TGF-ß1 expression, but not podocyte Pax-2 expression or loss of WT1, synaptopodin, {alpha}-actinin-4 or nephrin expression. However, podocytes in partially sclerotic glomeruli that still expressed WT1 at high levels showed reduced vimentin expression, cell cycle re-entry, and re-expressed desmin, cytokeratin and Pax-2. The results suggest that: (i) GS is not due to loss of WT1 expression by podocytes; (ii) podocyte Pax-2 expression reflects re-expression rather than persistent expression, and is the consequence of GS; (iii) GS is mediated systemically and the mechanism involves activation of the renin–angiotensin system; and (iv) podocytes undergo typical maturational changes but subsequently de-differentiate and revert to an immature phenotype during disease progression.

* To whom correspondence should be addressed. Tel: +44 1316511078; Fax: +44 1316511072; Email: m.hooper{at}ed.ac.uk

{dagger} Present address: Institute of Human Genetics, International Centre for Life, Central Parkway, Newcastle-upon-Tyne NE1 3B7, UK.

{ddagger} Present address: Centre for Research in Biomedicine, Faculty of Applied Sciences, University of the West of England, Bristol BS16 1QY, UK.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
A. A. Morrison, R. L. Viney, M. A. Saleem, and M. R. Ladomery
New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes
Am J Physiol Renal Physiol, July 1, 2008; 295(1): F12 - F17.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
S. E. Quaggin and J. A. Kreidberg
Development of the renal glomerulus: good neighbors and good fences
Development, February 15, 2008; 135(4): 609 - 620.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
L. Kaufman, G. Yang, K. Hayashi, J. R. Ashby, L. Huang, M. J. Ross, M. E. Klotman, and P. E. Klotman
The homophilic adhesion molecule sidekick-1 contributes to augmented podocyte aggregation in HIV-associated nephropathy
FASEB J, May 1, 2007; 21(7): 1367 - 1375.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. V. Dandapani, H. Sugimoto, B. D. Matthews, R. J. Kolb, S. Sinha, R. E. Gerszten, J. Zhou, D. E. Ingber, R. Kalluri, and M. R. Pollak
{alpha}-Actinin-4 Is Required for Normal Podocyte Adhesion
J. Biol. Chem., January 5, 2007; 282(1): 467 - 477.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
B. Smeets, M. L. M. Steenbergen, H. B. P. M. Dijkman, K. N. Verrijp, N. A. J. M. te Loeke, J. Aten, E. J. Steenbergen, and J. F. M. Wetzels
Angiotensin converting enzyme inhibition prevents development of collapsing focal segmental glomerulosclerosis in Thy-1.1 transgenic mice
Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3087 - 3097.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
P. Hohenstein and N. D. Hastie
The many facets of the Wilms' tumour gene, WT1
Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R196 - R201.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
K. Tryggvason, J. Patrakka, and J. Wartiovaara
Hereditary proteinuria syndromes and mechanisms of proteinuria.
N. Engl. J. Med., March 30, 2006; 354(13): 1387 - 1401.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. Rico, A. Mukherjee, M. Konieczkowski, L. A. Bruggeman, R. T. Miller, S. Khan, J. R. Schelling, and J. R. Sedor
WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment
Am J Physiol Renal Physiol, August 1, 2005; 289(2): F431 - F441.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
M. S. Orloff, S. K. Iyengar, C. A. Winkler, K. A. B. Goddard, R. A. Dart, T. S. Ahuja, M. Mokrzycki, W. A. Briggs, S. M. Korbet, P. L. Kimmel, et al.
Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population
Physiol Genomics, April 14, 2005; 21(2): 212 - 221.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Zenker, T. Aigner, O. Wendler, T. Tralau, H. Muntefering, R. Fenski, S. Pitz, V. Schumacher, B. Royer-Pokora, E. Wuhl, et al.
Human laminin {beta}2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities
Hum. Mol. Genet., November 1, 2004; 13(21): 2625 - 2632.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. B. Srichai, M. Konieczkowski, A. Padiyar, D. J. Konieczkowski, A. Mukherjee, P. S. Hayden, S. Kamat, M. A. El-Meanawy, S. Khan, P. Mundel, et al.
A WT1 Co-regulator Controls Podocyte Phenotype by Shuttling between Adhesion Structures and Nucleus
J. Biol. Chem., April 2, 2004; 279(14): 14398 - 14408.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
M. T. Discenza and J. Pelletier
Insights into the physiological role of WT1 from studies of genetically modified mice
Physiol Genomics, February 13, 2004; 16(3): 287 - 300.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.